StockNews.com Begins Coverage on DBV Technologies (NASDAQ:DBVT)

Investment analysts at StockNews.com initiated coverage on shares of DBV Technologies (NASDAQ:DBVT) in a research report issued on Thursday. The brokerage set a “hold” rating on the stock.

A number of other research analysts have also recently commented on DBVT. JMP Securities reaffirmed a “market outperform” rating and set a $10.00 target price on shares of DBV Technologies in a research note on Tuesday, December 10th. HC Wainwright raised their target price on shares of DBV Technologies from $25.00 to $35.00 and gave the company a “buy” rating in a research report on Thursday, October 24th.

DBV Technologies Stock Performance

NASDAQ DBVT opened at $3.83 on Thursday. DBV Technologies has a fifty-two week low of $2.20 and a fifty-two week high of $9.50. The company has a market cap of $78.78 million, a P/E ratio of -0.85 and a beta of 0.64. The business’s 50 day moving average price is $3.29 and its 200-day moving average price is $3.82.

DBV Technologies Company Profile

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis.